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Zinc, hydrochlorothiazide 
and sexual dysfunction
SM KHEDUN, * T NAICKER, B MAHARAJ 
SUMMARY
This study was designed to test the hypothesis that 
hydrochlorothiazide a diuretic used to treat hyperten­
sion depletes body zinc and thereby cause sexual dys­
function. Serum zinc and sexual dysfunction were 
measured in 39 middle aged hypertensive men who had 
been taking hydrochlorothiazide in average daily doses 
of between 25 and 50 mg daily for at least six months, 
and a control group of 27 unmedicated middle aged 
normotensive men. The medicated group had a higher 
incidence of sexual dysfunction (56 pc) as compared to 
11 pc in the control group. The use of hydrochlo­
rothiazide did affect serum zinc levels significantlyin 
20 patients. Sexual dysfunction occurred more often in 
older and overweight patients (p < 0,004). Three of the 
normotensive men experienced sexual dysfunction 
probably related to old age.
Twenty two of the 39 on hydrochlorothiazide and 
experiencing sexual dysfunction were divided into two 
groups of 11 patients. Bloods were taken from the 27 
normotensive and 22 hypertensive men receiving 
hydrochlorothiazide for the analyses of zinc. Subse­
quently one group of the patients were supplemented 
with zinc 500 mg daily for 30 days while the other 
group was supplemented with magnesium chloride 1 g 
daily for 30 days. The normotensive men were not 
treated. After 30 days, bloods were again taken from 
the three groups of analyses for zinc and magnesium.
Serum zinc was significantly decreased (p < 0,05) by 
hydrochlorothiazide and a non significant decrease in
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serum magnesium (p= ns) was observed. After supple­
mentation with zinc, the serum zinc levels returned to 
normal only in eight patients. There was improvement 
in the symptoms of sexual dysfunction in five patients. 
Two patients gained weight.
Hydrochlorothiazide decreased serum zinc levels 
(p < 0,05) and was unchanged with magnesium supple­
mentation but the serum magnesium returned to nor­
mal values. Improvement of symptoms of sexual dys­
function was positive in one patient.
This study shows that low serum zinc levels may be 
associated with sexual dysfunction but the definitive 
role of zinc in the pathogenesis of sexual dysfunction 
will remain controversial.
INTRODUCTION
Hydrochlorothiazide, a thiazide diuretic, is widely use 
in the treatment of mild to moderate hypertension. A 
common side effect experienced by our Black male 
patients on hydrochlorothiazide treatment for blood 
pressure control is sexual dysfunction. Hydrochlo­
rothiazide causes increased potassium, magnesium and 
zinc excretion.1
Magnesium is gaining recognition as a clinically 
important electrolyte in that it helps in the restoration 
and the movements of ions across membranes. It af­
fects the functioning of pumps,2 carriers3 and chan­
nels.4 Based on these diverse functions of magnesium, 
it was hypothesised that magnesium supplementation 
might help in the restoration of serum zinc to normal 
levels.
Zinc is an essential element of more than 200 en­
zymes and is involved in the metabolism of nucleic 
acids, protein synthesis and normal functioning of the 
immune system. Growth retardation, delayed wound 
healing, glucose intolerance, hyperlipidemia, skin 
changes, hypogonadism and impotence are the charac­
teristics of zinc deficiency.5
A study was conducted to determine whether mag­
nesium or zinc supplementation given to patients on 
hydrochlorothiazide treatment for blood pressure con­
trol would restore their serum zinc to normal levels and 
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MATERIALS AND METHODS
The protocols were approved by the Ethics Committee, 
University of Natal Medical School. Informed consent 
was obtained from all patients. Twenty four normoten- 
sive men served as control for both the study groups. 
Protocol 1.
Eleven Black male patients receiving hydrochloro­
thiazide ranging from 25 to 50 mg once daily for blood 
pressure treatment experiencing sexual dysfunction 
took part in the study. Bloods were collected for serum 
zinc and magnesium analyses. These patients were 
supplemented with 1 gm magnesium chloride daily. 
After 30 days serum zinc and magnesium levels were 
measured.
Protocol 2.
Another 11 Black male patients experiencing sexual 
dysfunction on hydrochlorothiazide on a dose of 25 to 
50 mg once daily for blood pressure treatment were 
included in the study. Blood was collected for serum 
zinc analyses. These patients were supplemented with 
500 mg zinc sulphate for 30 days and subsequently 
serum zinc was analysed. Serum zinc and magnesium 
levels were analysed by Natal Regional Laboratories, 
King Edward VIII Hospital, Durban.
RESULTS
The patients in both groups were aged between 52 and 
68 years. Their bodymass ranged between 76 to 109 kg 
and height from 162 to 187 cm. Hydrochlorothiazide 
was effective in controlling blood pressure.
Protocol 1.
Serum zinc was significantly decreased (p < 0,05; 
Table I) and a non significant decrease in serum mag­
nesium (p = ns; Table I) was observed. After supple­
mentation with magnesium chloride, the serum zinc 
levels were unchanged but the serum magnesium lev­
els returned to normal values. There was improvement 
in the symptoms of sexual dysfunction in one of the 
patients. Serum zinc levels before and after magnesium 
supplementation are presented in Table I.
Protocol 2.
Hydrochlorothiazide decreased serum zinc levels 
(p < 0,05; Table II) and was corrected with zinc 
supplementation only in eight patients. Improvement 
of symptoms of sexual dysfunction was positive in four 
patients. Two patients gained weight Serum zinc lev­
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Table I: Serum magnesium and zinc levels before and after magnesium chloride supplementation in patients on 
hydrochlorothiazide in a range o f  25 to 50 mg daily for blood pressure treatment. Results are expressed as
m ean±SD .
Experimental (n = 11)
Normal range Control





Zinc(pm oM) 11,6-19,1 13,67 ±2,23 7,8 ±1,67* 15,8 ±2,3
‘p<0,05.
Table II:Serum zinc levels before and after zinc supplementation in patients taking hydrochlorothiazide 25 to 
50 m gdailyfor blood pressure treatment. Results are expressed as mean ±  SD.
Experimental (n -1 1 )
Normal range Control before after
(n -2 7 ) supplementation supplementation
Zinc (p mol/l) 11,60-19,1 13,67 ±2,23 7,3 ±1,6* 6,69 ±1,35
Magnesium
(mmd/l)
0,74-0,99 0,95 ±0,03 0,90 ±0,06 1,09 ±1.1
*p <  0,05.
DISCUSSION
Although the value of treating hypertension has been 
well established, a substantial number of patients fail to 
comply with drug therapy and thus do not receive the 
benefits of blood pressure reduction because there is 
growing evidence suggesting an increase in drug in­
duced sexual dysfunction among antihypertensive 
agents.6-7 In a study com paring prazosin and 
hydrochlorothiazide in sexual dysfunction, decrements 
in buckling pressure and subjective aspects of sexual 
dysfunction were greater during hydrochlorothiazide 
treatment than during prazosin treatment.8
In a large clinical trial of zinc supplementation, zinc 
depleted subjects showed a remarkable increase in 
height, body weight and gonadal development follow­
ing zinc supplementation.9 In our study, there was a 
significant decrease in serum zinc and anon significant 
decrease in serum magnesium. After supplementation 
with magnesium chloride, the serum zinc levels showed 
no change but the serum magnesium levels were cor­
rected. Improvement of sexual dysfunction was ob­
served in one patient.
Zinc supplementation corrected serum zinc levels in 
80 pc of patients and improvement of sexual dysfunc­
tion was observed in 36 pc of patients.
It is possible that low serum zinc levels may be 
associated with sexual dysfunction. Until other clinical 
factors have been studied, the definitive role of zinc in 
the pathogenesis of sexual dysfunction will remain 
controversial. It is important to obtain adequate history 
before and alter initiating antihypertensive drug therapy. 
If sexual dysfunction develops in a patient, a different 
class of medication can be tried.
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Neuropsychiatric HIV-1 
infection study: in Kenya 
and Zaire cross-sectional 
phase I and II
MB SEBIT 
SUMMARY
The objective of the study was to determine the preva­
lence and natural history of human immunodeficiency 
virus type 1 (HIV-1) associated psychiatric, neuropsy­
chological and neurological abnormalities. A total of 
408 subjects were recruited in Nairobi and Kinshasa. 
The study consisted of a cross sectional phase and a 
longitudinal follow up.
Assessment was made by a data collection instru­
ment including six modules. The intercentre and 
intracentre reliability in the use of the each module 
have been formally evaluated. The mean global score 
on the Montgomery-Asberg Depression Rating Scale
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was significantly higher in symptomatic seropositive 
individuals than in matched seronegative controls.
In conclusion, these data suggest that the risk of 
subtle cognitive deficits may be increased in 
asymptomatic stages of HIV-1 infection.
INTRODUCTION
The presence of psychological problems in people with 
human immunodeficiency virus type one (HIV-1) in­
fection has been the subject of considerable attention 
recently. According to world wide estimates by the 
World Health Organization (WHO),1 85 pc of adults 
infected with HTV-1 live outside Western industrial­
ized countries. Over 75 pc of infections in adults are 
transmitted through heterosexual intercourse and more 
than 45 pc of infected subjects are women.
Most of the available evidence comes from surveys 
of well educated, mostly White homosexual men2'*, or 
gays and drug users.5 A series of studies has shown an 
increased vulnerability to psychological distress and a 
significant prevalence of psychiatric disorders associ­
ated with HIV-1 infection, ranging from 30 to 63 pc.6,7 
Furthermore, infection with HIV-1 may leadtoanum- 
ber of neurological complications, one of the most 
important of which is AIDS dementia complex.8
The incidence of HIV-1 dementia is approximately 
seven per 100 patients per year following development 
of AIDS, with up to 20 pc of HIV-1 infected individuals 
receivingadiagnosisofHIV-1 dementia before death.910 
However, a recent study has found no significant de­
cline in cognitive functions before AIDS, unless overt 
dementia is present.11
Concerns about generalization of the currently avail­
able information on the psychiatric, as well as the 
neuropsychological and neurological complications of 
HIV-iinfection has prompted the World Health Orga­
nization to implement the cross-cultural venture called 
World Health Organization Neuropsychiatric AIDS 
Study. The project’s objective was to assess the preva­
lence and the natural history of the above mentioned 
complications in these two geographic areas, with 
respect to sex ratio and distribution of HIV-1 in at-risk 
groups.
MATERIALS AND METHODS
Subjects: A total o f408 subjects (n = 203 in Nairobi, 
Kenya and n = 205 in Kinshasa, Zaire) was recruited 
between October 1990 and August 1991, to participate 
in a cross-section (phase I and II) study. The drop outs
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